Tacrolimus + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

IgA Nephropathy

Conditions

IgA Nephropathy

Trial Timeline

Nov 1, 2010 → Jun 1, 2011

NCT ID

NCT01224028

About Tacrolimus + Placebo

Tacrolimus + Placebo is a phase 2 stage product being developed by Astellas Pharma for IgA Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01224028. Target conditions include IgA Nephropathy.

What happened to similar drugs?

6 of 20 similar drugs in IgA Nephropathy were approved

Approved (6) Terminated (3) Active (11)

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

✅CyclosporineNovartisApproved

✅ForxigaNovo NordiskApproved

✅nisoldipine + lisinoprilBayerApproved

✅Intravenous Rituximab + ACE/ARBBiogenApproved

🔄olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01224028	Phase 2	Completed	Nov 1, 2010	Jun 1, 2011	IgA Nephropathy
NCT00347048	Phase 3	Completed	Sep 1, 2006	Apr 1, 2008	Ulcerative Colitis
NCT00319917	Approved	Completed	Apr 1, 2006	Oct 1, 2008	Rheumatoid Arthritis
NCT00309088	Phase 3	Completed	Apr 1, 2006	Jun 1, 2008	Myasthenia Gravis
NCT00106392	Approved	Completed	Feb 1, 2005	Nov 1, 2008	Erectile Dysfunction

Competing Products

20 competing products in IgA Nephropathy

See all competitors

Product	Company	Stage	Hype Score
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	32
Placebo + LY3016859	Eli Lilly	Phase 1/2	32
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1	Eli Lilly	Pre-clinical	26
HR19042 Capsules + Placebo	Jiangsu Hengrui Medicine	Phase 2	35
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 capsule	Jiangsu Hengrui Medicine	Phase 1	29
Atrasentan + Placebo	AbbVie	Phase 3	32
Atrasentan	AbbVie	Phase 2	35
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
ALXN1920 + Placebo	AstraZeneca	Phase 2	42
Candesartan	AstraZeneca	Pre-clinical	26
Placebo + Atacicept 25 mg + Atacicept 75 mg	Merck	Phase 2	27
BION-1301 + Placebo	Novartis	Phase 3	44
MAU868 + Placebo	Novartis	Phase 2	27
Atrasentan	Novartis	Phase 2	39
Cyclosporine	Novartis	Approved	39